What Is Your Medspa Worth? Valuation & EBITDA Multiples

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It represents the cash profit your practice generates before financing and accounting adjustments. Buyers use EBITDA multiples because they isolate operational performance from capital structure and tax situations.

Medspa valuations typically range across three tiers:

• Small/Solo practices (under $1M EBITDA): typically 3–6x EBITDA
• Established independent practices ($1–3M EBITDA): typically 7–12x EBITDA
• Larger platforms or aggregators ($3M+ EBITDA): up to 15–20x EBITDA or higher

These multiples reflect the buyer's confidence in the practice's stability, growth trajectory, and ability to retain revenue after ownership change. A solo injector with high provider dependence may command a lower multiple; an established multi-provider clinic with strong systems and recurring revenue may command a premium.

Your EBITDA multiple is not fixed—it moves based on operational and market factors:

Factors that increase your multiple:

• Provider diversification: Multiple injectors, aestheticians, or laser technicians reduce buyer risk
• Recurring revenue & loyalty: Strong patient retention, membership programs, and repeat treatment plans
• Scalable systems: Documented protocols, staff training, and technology (EMR, CRM) that survive ownership transition
• Clean financials: Audited or reviewed statements, clear revenue recognition, minimal owner discretionary expenses
• Growth trajectory: Year-over-year revenue and EBITDA growth signal market strength
• Brand & location: Established reputation, prime real estate, or defensible patient base
• Contractual stability: Long-term supplier agreements, favorable lease terms, or exclusive product rights

Factors that decrease your multiple:

• Provider concentration: Revenue heavily dependent on one injector or owner
• Regulatory or compliance risk: Pending licensing issues, scope-of-practice disputes, or prior violations
• Customer churn: High patient turnover or seasonal revenue patterns
• Aging equipment or facility: Deferred capital expenditure or obsolete technology
• Market saturation: Declining patient acquisition or price compression in your geography

Not all valuations are paid the same way. Understanding deal structure is critical to your net proceeds:

All-cash deals:

• Buyer pays the full purchase price in cash at close
• You receive 100% of the valuation immediately
• Typically used by large aggregators or private equity firms with capital
• May include earnouts (contingent payments tied to post-close performance)

Rollover equity (or "roll"):

• You retain a minority stake in the combined entity (often 5–20%)
• Receive partial cash at close; remainder tied to future value creation
• Common in platform builds where buyer wants seller alignment
• Your equity may appreciate if the platform grows, but it's illiquid and carries ongoing risk

Hybrid structures:

• Combination of cash and equity, with earnouts based on EBITDA targets or patient retention
• Earnouts typically last 1–3 years and can represent 10–30% of total consideration
• Protects buyer from revenue loss post-close; incentivizes seller to ensure smooth transition

Always clarify the cash at close versus total consideration, and understand any clawback provisions if targets are missed.

When you receive a letter of intent (LOI) or term sheet, the headline multiple is only part of the story. Pay attention to:

Purchase price and calculation:

• Is it based on trailing twelve months (TTM) EBITDA or a forward projection?
• Are there add-backs for owner compensation, rent, or one-time expenses?
• Does the buyer adjust EBITDA for non-recurring items (e.g., legal fees, equipment sales)?

Working capital and adjustments:

• Buyer may hold back cash or escrow funds to cover post-close liabilities
• Understand the target working capital and how variances are settled
• Clarify who owns accounts receivable and patient deposits

Earnout and contingencies:

• If part of the deal is contingent, what are the specific metrics (revenue, EBITDA, patient retention)?
• Over what time period are they measured?
• Who controls the business during the earnout period, and can the buyer make changes that affect your payout?

Representations and indemnification:

• Seller indemnity clauses can expose you to liability after close
• Typical indemnity periods are 12–24 months; negotiate caps and baskets
• Understand your personal guarantee obligations and tail insurance requirements

The aesthetic industry has seen significant consolidation and acquisition activity in recent years. Large platforms and private equity firms continue to acquire independent practices, though valuations have moderated from peak multiples seen in 2021–2022.

Key market drivers:

• Product innovation: FDA approvals for new injectables (e.g., Skinvive by Juvéderm for neck lines, RHA Dynamic Volume for midface) expand treatment menus and drive patient volume
• Regulatory environment: State scope-of-practice rules, licensing requirements for injectors, and compliance costs affect profitability and buyer appetite
• Consolidation trends: Larger platforms (aggregators backed by private equity) are actively acquiring independent practices to build regional or national footprints
• Provider supply: Shortage of qualified injectors in some markets supports higher valuations; oversupply in urban centers may compress multiples

Stay informed about FDA approvals, state regulatory changes, and competitor acquisitions in your market. These signals affect buyer confidence and your negotiating position.

If you're considering a sale in the next 1–3 years, start now:

Financial preparation:

• Maintain clean, audited or reviewed financial statements
• Document all revenue streams (injectables, laser, skincare, memberships) separately
• Separate owner discretionary expenses from true operating costs
• Build a 3-year financial history showing consistent or growing EBITDA

Operational readiness:

• Cross-train staff to reduce provider dependence
• Document all protocols, supplier agreements, and patient acquisition channels
• Ensure compliance with state licensing, scope-of-practice, and advertising rules
• Build recurring revenue through memberships, package deals, or subscription models

Professional support:

• Engage a business broker or M&A advisor familiar with aesthetic practices (not just general business brokers)
• Consult a tax advisor to understand the tax implications of different deal structures
• Work with an attorney to review LOIs and purchase agreements before signing

These investments typically pay for themselves many times over in a successful exit.

You don't need to hire an advisor immediately, but do your homework:

Understand your EBITDA:

• Calculate your trailing twelve-month EBITDA using your most recent financial statements
• Identify any one-time expenses or add-backs that a buyer might normalize
• Compare your margins to industry benchmarks (typically 20–35% EBITDA margin for established practices)

Research comparable transactions:

• Ask your industry peers (off the record) about recent sales or valuations in your region
• Follow SEC filings for public aesthetic companies and aggregators (AbbVie/Allergan Aesthetics, Evolus, InMode) to track acquisition activity and pricing trends
• Review trade publications (Dermatology Times, MedEsthetics) for market commentary

Assess your risk factors:

• Identify any regulatory, compliance, or operational risks that might lower your multiple
• Evaluate your provider concentration and patient retention metrics
• Understand your lease terms, supplier contracts, and equipment condition

Connect with advisors when ready:

• A business broker or investment banker can provide a formal valuation and market overview
• Many offer free initial consultations; use this to gauge their expertise in aesthetic practices
• Ask for references from recent seller clients and verify their track record

Your practice's value is real—understanding how it's measured is the first step to maximizing it.

Independent medspas are valued on EBITDA multiples (typically 3–20x depending on size and stability), adjusted for provider concentration, growth, and operational risk. Offers may include cash, equity rollover, or earnouts; always clarify the cash at close and understand contingencies. Start preparing your financials and operations now if you're thinking about an exit in the next few years—clean systems and diversified revenue streams command premium multiples. Engage a broker or M&A advisor familiar with aesthetic practices to guide you through the process.